References

Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000−2021: a systematic analysis from the Global Burden of Disease Study 2021

10.1016/s2352-3026(23)00118-7 · 2023 · External reference

Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission

10.1016/s2352-3026(23)00096-0 · 2023 · External reference

Global burden of sickle cell anaemia in children under five, 2010‐2050: modelling based on demographics, excess mortality, and interventions

10.1371/journal.pmed.1001484 · 2013 · External reference

Sickle cell disease

10.1016/s0140-6736(17)30193-9 · 2017 · External reference

The clinical spectrum of HbSC sickle cell disease‐not a benign condition

10.1111/bjh.19523 · 2024 · External reference

The paradox of hemoglobin SC disease

10.1016/s0268-960x(03)00003-1 · 2003 · External reference

The clinical significance of K‐Cl cotransport activity in red cells of patients with HbSC disease

10.3324/haematol.2014.120402 · 2015 · External reference

Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea

10.1002/ajh.27074 · 2023 · External reference

Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis

10.1182/blood-2018-10-880575 · 2019 · External reference

AGREE II: advancing guideline development, reporting and evaluation in health care

10.1503/cmaj.090449 · 2010 · External reference

Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology Guideline

10.1111/bjh.18794 · 2023 · External reference

The Danish national haemoglobinopathy screening programme: report from 16 years of screening in a low‐prevalence, non‐endemic region

10.1111/bjh.19103 · 2024 · External reference

Sickle cell anemia in Cuba: prevention and management, 1982‐2018

2019 · External reference

Parents' experiences of universal screening for haemoglobin disorders: implications for practice in a new genetics era

10.3399/bjgp08x277276 · 2008 · External reference

Genetic carrier screening for cystic fibrosis, Fragile X Syndrome, hemoglobinopathies, and spinal muscular atrophy

2021 · External reference

EHA recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies

10.1002/hem3.70381 · 2026 · External reference

Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies

10.1002/hem3.70381 · 2026 · External reference

Prenatal genetic counseling in cross‐cultural medicine: a framework for family physicians

2010 · External reference

Who counsels parents of newborns who are carriers of sickle cell anemia or cystic fibrosis?

10.1007/s10897-012-9537-3 · 2013 · External reference

Point‐of‐care diagnostic test accuracy in children and adolescents with sickle cell disease: a systematic review and meta‐analysis

10.1016/j.blre.2024.101243 · 2025 · External reference

Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta‐analysis

10.1002/uog.20353 · 2019 · External reference

Non‐invasive prenatal testing for the diagnosis of sickle cell disease in high‐risk pregnancies: a systematic review and statistical summary of the current literature

10.1016/j.ejogrb.2025.114799 · 2026 · External reference

Knowledge insufficient: the management of haemoglobin SC disease

10.1111/bjh.14444 · 2017 · External reference

Seeing haemoglobin SC: challenging the misperceptions

10.1111/bjh.19580 · 2024 · External reference

Perceptions of patients and stakeholders on a prenatal sickle cell disease screening and its results among tribal populations of Gujarat: a participatory mixed‐method research

10.1007/s12687-025-00768-5 · 2025 · External reference

Sickle cell retinopathy: improving care with a multidisciplinary approach

10.2147/jmdh.s90630 · 2017 · External reference

Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11‐year follow‐up study

10.1182/bloodadvances.2022009147 · 2023 · External reference

Rétinopathie drépanocytaire: analyse rétrospective portant sur 730 patients suivis dans un centre de référence

External reference

Impaired blood rheology plays a role in the chronic disorders associated with sickle cell‐hemoglobin C disease

10.3324/haematol.2014.104745 · 2014 · External reference

Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence

10.3324/haematol.2024.286420 · 2025 · External reference

Anti‐vascular endothelial growth factor therapy for stages 3 and 4 proliferative sickle cell retinopathy results in improved anatomical and visual outcomes

10.1097/iae.0000000000004658 · 2026 · External reference

Central nervous system complications and management in sickle cell disease

10.1182/blood-2015-09-618579 · 2016 · External reference

Neuropsychologic performance in school‐aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease

10.1067/mpd.2001.116935 · 2001 · External reference

Higher‐than‐expected prevalence of silent cerebral infarcts in children with hemoglobin SC disease

10.1182/blood-2014-10-605964 · 2015 · External reference

Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC disease: a retrospective single institution study

10.1159/000519360 · 2022 · External reference

Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC)

10.3324/haematol.2020.265827 · 2021 · External reference

Cerebrovascular accidents in sickle cell disease: rates and risk factors

1998 · External reference

The excess burden of stroke in hospitalized adults with sickle cell disease

10.1002/ajh.21476 · 2009 · External reference

Transcranial Doppler scanning and the assessment of stroke risk in children with haemoglobin sickle cell disease

10.1136/adc.2007.125799 · 2008 · External reference

Transcranial Doppler in hemoglobin SC disease

10.1002/pbc.26342 · 2017 · External reference

American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults

10.1182/bloodadvances.2019001142 · 2020 · External reference

Do statins improve outcomes after acute ischemic stroke?

10.1038/nrneurol.2011.92 · 2011 · External reference

Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association

10.1161/str.0b013e3181f7d043 · 2011 · External reference

Hemoglobin sickle cell disease complications: a clinical study of 179 cases

10.3324/haematol.2011.055202 · 2012 · External reference

Treatment of sickle cell disease's hip necrosis by core decompression: a prospective case‐control study

10.1016/j.otsr.2009.07.009 · 2009 · External reference

Sickle cell disease as a cause of osteonecrosis of the femoral head

10.1056/nejm199111213252104 · 1991 · External reference

Does increased red blood cell deformability raise the risk for osteonecrosis in sickle cell anemia?

10.1182/blood-2013-01-480277 · 2013 · External reference

Sickle cell bone disease and response to intravenous bisphosphonates in children

10.1007/s00198-022-06455-2 · 2022 · External reference

Stem cell therapy for the treatment of hip osteonecrosis: a 30‐year review of progress

10.4055/cios.2016.8.1.1 · 2016 · External reference

Total hip arthroplasty in sickle cell disease: a systematic review and meta‐analysis of functional outcomes and complications

10.1016/j.jcot.2025.103060 · 2025 · External reference

Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia

10.1016/s0002-9343(96)00407-x · 1997 · External reference

Weight status of children with sickle cell disease

10.1542/peds.2012-2225 · 2013 · External reference

High body mass index in children with sickle cell disease: a retrospective single‐centre audit

10.1136/bmjpo-2018-000302 · 2018 · External reference

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease

10.1056/nejmoa035477 · 2004 · External reference

Cardiac manifestations in sickle cell disease varies with patient genotype

10.1111/bjh.15238 · 2018 · External reference

Elevated hypercoagulability markers in hemoglobin SC disease

10.3324/haematol.2014.114587 · 2015 · External reference

Venous thromboembolism in adults with sickle cell disease: a serious and under‐recognized complication

10.1016/j.amjmed.2012.12.016 · 2013 · External reference

Causes of death in sickle cell disease: an autopsy study

10.1046/j.1365-2141.2003.04594.x · 2003 · External reference

Risk factors for venous thromboembolism in adults with hemoglobin SC or Sβ+ thalassemia genotypes

10.1016/j.thromres.2016.03.003 · 2016 · External reference

Coronavirus disease among persons with sickle cell disease, United States, March 20‐May 21, 2020

10.3201/eid2610.202792 · 2020 · External reference

Glomerular hyperfiltration and albuminuria in children with sickle cell anemia

10.1007/s00467-011-1857-2 · 2011 · External reference

Kidney disease among patients with sickle cell disease, hemoglobin SS and SC

10.2215/cjn.03940415 · 2016 · External reference

Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality

10.7326/0003-4819-115-8-614 · 1991 · External reference

Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea

10.1002/(sici)1096-8652(200005)64:1<47::aid-ajh8>3.0.co;2-1 · 2000 · External reference

Gallstones in sickle cell disease: observations from The Jamaican Cohort study

10.1016/s0022-3476(00)90054-4 · 2000 · External reference

Outcome in hemoglobin SC disease: a four‐decade observational study of clinical, hematologic, and genetic factors

10.1002/ajh.10140 · 2002 · External reference

Functional asplenia in hemoglobin SC disease

10.1182/blood.v85.8.2238.bloodjournal8582238 · 1995 · External reference

Relevance of Howell‐Jolly body counts for measuring spleen function in sickle cell disease

10.1002/ajh.26879 · 2023 · External reference

Palpable splenomegaly in children with haemoglobin SC disease: haematological and clinical manifestations

10.1046/j.1365-2257.2000.00304.x · 2000 · External reference

Acute splenic complications in children with sickle cell‐hemoglobin C disease

10.1016/s0022-3476(97)70284-1 · 1997 · External reference

Priapism in sickle‐cell disease; incidence, risk factors and complications—an international multicentre study

10.1046/j.1464-410x.2002.03022.x · 2002 · External reference

How I treat priapism

10.1182/blood-2014-09-551887 · 2015 · External reference

Epidemiology and treatment of priapism in sickle cell disease

10.1182/hematology.2022000380 · 2022 · External reference

European Association of Urology guidelines on priapism

10.1016/j.eururo.2013.11.008 · 2014 · External reference

American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support

10.1182/bloodadvances.2019001143 · 2020 · External reference

Risk factors for alloimmunization by patients with sickle cell disease

10.1590/s0100-879x2005000500004 · 2005 · External reference

Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease

10.1182/bloodadvances.2022008647 · 2023 · External reference

How I safely transfuse patients with sickle‐cell disease and manage delayed hemolytic transfusion reactions

10.1182/blood-2018-02-785964 · 2018 · External reference

Cellular effects of hydroxyurea in Hb SC disease

10.1046/j.1365-2141.1997.3173132.x · 1997 · External reference

A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea

10.1182/blood.2024028136 · 2025 · External reference

Management of sickle cell disease: summary of the 2014 evidence‐based report by expert panel members

10.1001/jama.2014.10517 · 2014 · External reference

Hydroxyurea treatment of children with hemoglobin SC disease

10.1002/pbc.24283 · 2013 · External reference

Hydroxyurea therapy for pediatric patients with hemoglobin SC disease

10.1097/00043426-200106000-00014 · 2001 · External reference

Effects of hydroxyurea treatment for patients with hemoglobin SC disease

10.1002/ajh.24255 · 2016 · External reference

Hydroxyurea for children and adults with hemoglobin SC disease

2025 · External reference

Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub‐Saharan Africa

10.1111/bjh.19832 · 2024 · External reference

Iron deficiency in HbSC disease treated with repetitive phlebotomy is associated with fewer sickle cell disease‐related complications

10.1002/ajh.70045 · 2025 · External reference

Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC

10.1111/bjh.70262 · 2026 · External reference

Iron restriction is an important treatment of hemoglobin SC disease

10.1002/ajh.24380 · 2016 · External reference

Original research: use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease

10.1177/1535370216639737 · 2016 · External reference

Recommendations for diagnosis, treatment, and prevention of iron deficiency and iron deficiency anemia

10.1002/hem3.108 · 2024 · External reference

Iron deficiency is associated with reduced levels of inflammation and haemolysis in patients with HbSS and HbSC and reduced clinical admissions in those with HbSC

10.1111/bjh.70262 · 2026 · External reference

Crizanlizumab for the prevention of pain crises in sickle cell disease

10.1056/nejmoa1611770 · 2017 · External reference

A phase 3 trial of l‐glutamine in sickle cell disease

10.1056/nejmoa1715971 · 2018 · External reference

Emerging therapies in sickle cell disease

10.1111/bjh.16504 · 2020 · External reference

The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease

10.1182/blood.2021014716 · 2022 · External reference

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double‐blind, randomised, placebo‐controlled trial

10.1016/s2352-3026(24)00319-3 · 2025 · External reference

Iron restricted erythropoiesis under hepcidin mimetic treatment (PN23114) improved disease parameters in a Mouse Model for sickle cell disease

10.1182/blood-2023-182472 · 2023 · External reference

Guidelines for the management of the acute painful crisis in sickle cell disease

10.1046/j.1365-2141.2003.04193.x · 2003 · External reference

Beyond IV push: alternative methods for management of acute pain in SCD

10.1182/hematology.2024000585 · 2024 · External reference

Acute chest syndrome is associated with history of asthma in hemoglobin SC disease

10.1002/pbc.22900 · 2011 · External reference

Causes and outcomes of the acute chest syndrome in sickle cell disease

10.1056/nejm200006223422502 · 2000 · External reference

Splenic complications in pediatric sickle cell disease: a retrospective cohort review

10.1002/pbc.31219 · 2024 · External reference

The spleen and sickle cell disease: the sick(led) spleen

10.1111/bjh.12950 · 2014 · External reference

Dengue in hospitalized children with sickle cell disease: a retrospective cohort study in the French departments of America

10.1016/j.jiph.2019.07.015 · 2020 · External reference

A retrospective analysis of the significance of haemoglobin SS and SC in disease outcome in patients with sickle cell disease and dengue fever

10.1016/j.ebiom.2015.07.002 · 2015 · External reference

Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units

10.1182/bloodadvances.2025015947 · 2025 · External reference

Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non‐SS genotypes and a possible association with human parvovirus B19 infection

10.1016/j.blre.2013.12.002 · 2014 · External reference

Low incidence of COVID‐19 severe complications in a large cohort of children with sickle cell disease: a protective role for basal interferon‐1 activation?

10.3324/haematol.2021.278573 · 2021 · External reference

An analysis of risk factors for sensorineural hearing loss in children with sickle cell disease

10.1097/mao.0000000000004674 · 2026 · External reference

Proactive management to improve outcomes of high‐risk pregnancy in people with sickle cell disease

10.1182/hematology.2025000744 · 2025 · External reference

Current obstetric outcomes in Jamaican women with sickle hemoglobinopathy—a balance of risks for aspirin?

10.1515/jpm-2023-0378 · 2024 · External reference

Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline

10.1111/bjh.17671 · 2021 · External reference

Hematopoietic stem cell transplantation in thalassemia and sickle cell disease: report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000−2017

10.1182/blood-2018-168 · 2018 · External reference

Allogeneic transplantation for sickle cell disease offers high rates of cure with low incidence of severe chronic GVHD in both children and adults: real world data from 2010‐2021. An analysis of the European Society for Blood and Bone Marrow Transplantation Haemoglobinopathy Registry

10.1182/blood-2024-207944 · 2024 · External reference

Sickle cell disease: an international survey of results of HLA‐identical sibling hematopoietic stem cell transplantation

10.1182/blood-2016-10-745711 · 2017 · External reference

Hematopoietic stem cell transplantation in sickle cell disease: a multidimentional review

10.1177/09636897241246351 · 2024 · External reference

Allogeneic hematopoietic stem‐cell transplantation for sickle cell disease

10.1056/nejmoa0904971 · 2009 · External reference

Selecting patients with sickle cell disease for gene addition or gene editing‐based therapeutic approaches: Report on behalf of a joint EHA Specialized Working Group and EBMT Hemoglobinopathies Working Party consensus conference

10.1002/hem3.70089 · 2025 · External reference

Gene therapy for HbSC disease and other compound heterozygous sickle hemoglobinopathies: a time for inclusion

10.1182/blood.2025029964 · 2025 · External reference

A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies

10.1182/bloodadvances.2025016793 · 2025 · External reference